China Resources Pharmaceutical Group Limited
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese… Read more
China Resources Pharmaceutical Group Limited (640) - Total Assets
Latest total assets as of June 2025: €286.85 Billion EUR
Based on the latest financial reports, China Resources Pharmaceutical Group Limited (640) holds total assets worth €286.85 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
China Resources Pharmaceutical Group Limited - Total Assets Trend (2016–2024)
This chart illustrates how China Resources Pharmaceutical Group Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
China Resources Pharmaceutical Group Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
China Resources Pharmaceutical Group Limited's total assets of €286.85 Billion consist of 72.1% current assets and 27.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 6.4% |
| Accounts Receivable | €81.56 Billion | 31.6% |
| Inventory | €37.05 Billion | 14.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €8.54 Billion | 3.3% |
| Goodwill | €22.37 Billion | 8.7% |
Asset Composition Trend (2016–2024)
This chart illustrates how China Resources Pharmaceutical Group Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: China Resources Pharmaceutical Group Limited's current assets represent 72.1% of total assets in 2024, an increase from 70.0% in 2016.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2024, down from 10.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 14.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 31.6% of total assets.
China Resources Pharmaceutical Group Limited Competitors by Total Assets
Key competitors of China Resources Pharmaceutical Group Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
China Resources Pharmaceutical Group Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - China Resources Pharmaceutical Group Limited generates 1.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, China Resources Pharmaceutical Group Limited generates $ 1.30 in net profit.
China Resources Pharmaceutical Group Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 1.37 | 1.20 |
| Quick Ratio | 1.12 | 1.12 | 0.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €58.74 Billion | € 53.62 Billion | € 23.00 Billion |
China Resources Pharmaceutical Group Limited - Advanced Valuation Insights
This section examines the relationship between China Resources Pharmaceutical Group Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.53 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.5% |
| Total Assets | €257.76 Billion |
| Market Capitalization | $940.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values China Resources Pharmaceutical Group Limited's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: China Resources Pharmaceutical Group Limited's assets grew by 4.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for China Resources Pharmaceutical Group Limited (2016–2024)
The table below shows the annual total assets of China Resources Pharmaceutical Group Limited from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €257.76 Billion | +4.45% |
| 2023-12-31 | €246.77 Billion | +2.27% |
| 2022-12-31 | €241.29 Billion | -2.93% |
| 2021-12-31 | €248.56 Billion | +18.72% |
| 2020-12-31 | €209.37 Billion | +10.18% |
| 2019-12-31 | €190.03 Billion | +7.82% |
| 2018-12-31 | €176.24 Billion | +9.64% |
| 2017-12-31 | €160.75 Billion | +19.98% |
| 2016-12-31 | €133.99 Billion | -- |